{
  "id": "5e4b5f566d0a277941000020",
  "type": "yesno",
  "question": "Is celecoxib effective for amyotrophic lateral sclerosis?",
  "ideal_answer": "No. In a clinical trial, celecoxib did not have a beneficial effect on patients with amyotrophic lateral sclerosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/18608093",
    "http://www.ncbi.nlm.nih.gov/pubmed/16802291"
  ],
  "snippets": [
    {
      "text": "In conclusion, the celecoxib-creatine combination was selected as preferable to the minocycline-creatine combination for further evaluation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18608093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ESULTS: Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\n\nAt the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\n\nCelecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\nCelecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}